Trial Profile
A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Temelimab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms ANGEL-MS
- Sponsors GeNeuro
- 03 Apr 2022 This trial has been completed in Hungary and Italy (End Date: 14 Nov 2018), according to European Clinical Trials Database record.
- 01 Mar 2022 Results from randomized phase 2b and extension study published in the Multiple Sclerosis Journal
- 16 Sep 2019 According to a GeNeuro media release, results of this extension study were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019) Congress (Stockholm, Sweden).